Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 22;37(10):1824-1829.
doi: 10.1093/ndt/gfac203.

Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group

Ilaria Gandolfini  1 , Marta Crespo  2 , Rachel Hellemans  3 , Umberto Maggiore  1 , Christophe Mariat  4 , Geir Mjoen  5 , Gabriel C Oniscu  6 , Licia Peruzzi  7 , Mehmet Sükrü Sever  8 , Bruno Watschinger  9 , Luuk Hilbrands  10
Affiliations

Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group

Ilaria Gandolfini et al. Nephrol Dial Transplant. .

Abstract

The Omicron variant, which has become the dominant strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, brings new challenges to preventing and controlling the infection. Moreover, the widespread implementation of vaccination policies before and after transplantation, and the development of new prophylactic and treatment strategies for coronavirus disease 2019 (COVID-19) over the past 12-18 months, has raised several new issues concerning kidney transplant recipients. In this special report, the ERA DESCARTES (Developing Education Science and Care for Renal Transplantation in European States) Working Group addresses several questions related to everyday clinical practice concerning kidney transplant recipients and to the assessment of deceased and live kidney donors: what is the current risk of severe disease and of breakthrough infection, the optimal management of immunosuppression in kidney transplant recipients with COVID-19, the role of passive immunization and the efficacy of antiviral drugs in ambulatory patients, the management of drug-to-drug interactions, safety criteria for the use of SARS-CoV-2-positive donors, issues related to the use of T cell depleting agents as induction treatment, and current recommendations for shielding practices.

Keywords: COVID-19; SARS-CoV-2; antiviral agents; kidney donation; kidney transplantation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hilbrands LB, Duivenvoorden R, Vart Pet al. . COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020; 35: 1973–83 - PMC - PubMed
    1. Jager KJ, Kramer A, Chesnaye NCet al. . Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 2020; 98: 1540–8 - PMC - PubMed
    1. Goffin E, Candellier A, Vart Pet al. . COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant 2021; 36: 2094–105 - PMC - PubMed
    1. Ao G, Wang Y, Qi Xet al. . The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando) 2021; 35: 100628. - PMC - PubMed
    1. Heldman MR, Kates OS, Safa Ket al. . Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. Am J Transplant 2022; 22: 279–88 - PMC - PubMed

Substances

Supplementary concepts